EHA returns to Cairo with the Highlights of the 24th EHA Congress

Cairo group photo HOPE MENA 2019

The 4th Highlights of Past EHA (HOPE) Middle East & North Africa (MENA) took place (for the third time) in Cairo, Egypt, organized in collaboration with the Pan Arab Hematology Association (PAHA) and hosted by the Egyptian Society of Hematology and Research (ESHR), and supported by the national hematology societies from the region, who were represented in the program as chairs of various sessions.

Read more

EHA’s Prof Jäger elected HCPWP co-chair

HCPWP co chairs Prof. Ulrich Jaeger EHA and Juan Garcia Burgos EMA

On September 24, Prof Ulrich Jäger, former EHA President and current member of the EHA European Affairs Committee, was elected as co-chair of the Health Care Professionals Working Party (HCPWP) of the European Medicines Agency (EMA). He will lead the working party during its 2019-2022 mandate alongside Juan Garcia-Burgos, EMA’s head of Public Engagement.

Read more

Without access to treatment, can we truly innovate in rare diseases?

HemAffairs Sept 24 v2

There have been many developments on rare diseases since the EU Orphan Medicinal Products Regulation came into force in 2000. As the European Commission is evaluating its effectiveness, EHA discussed with Prof. Giampaolo Merlini, Director of the Amyloidosis Research and Treatment Center and researcher at the Department of Molecular Medicine of the University of Pavia, how far we have come and what still needs to be done to improve access to treatment for rare diseases.

Read more

COST Action ‘EuNet-INNOCHRON’

HemAffairs Oct 3

The European Cooperation in Science and Technology (COST) is an EU-funded, intergovernmental framework that aims to create pan-European research networks in all science fields and promote excellence, foster interdisciplinary research and empower young researchers and innovators.

Read more

Open Access: the ‘Plan S’

HemAffairs Sept 24 v3

Research and academic groundwork funded with public means should be free and open to everyone. That is the principle behind Open Access that was formulated in 2003 in the Berlin Declaration. More than a decade has passed since and for years no significant action was taken. Scientific research, paid for by the taxpayer, is still mostly locked behind paywalls.

Read more

EHA Issues Recommendations on Mild to Moderate Bleeding Disorders

HemaSphere website block2

HemaSphere presents first in a series of Consensus Reports on Diagnosis of Inherited Bleeding Problems For hematologists, it can be challenging to make the correct diagnosis in patients with bleeding problems…

Read more

Meet Irene Roberts, our September volunteer of the month

Voulenteer of the month 3
Professor Irene Roberts started volunteering for EHA in 2003 and shortly afterwards was elected as a member of the EHA Board and then the Executive Board. She held many positions on various committees and currently Professor Roberts is a member of the EHA Global Outreach Program Committee. Meet Professor Roberts and learn about what she does and why she has been volunteering for EHA for all these years.
Read more

Meeting report | HOPE ASIA 2019 Kolkata

HOPE Asia cover image

The first edition of the Highlights of Past EHA (HOPE) in Asia was held in Kolkata, India and was a great success. The meeting was organized in collaboration with the Indian Society of Haematology and Blood Transfusion (ISHBT) and hosted by the Eastern Haematology Group (EHG), attended by over 600 participants from India, Nepal, Bangledesh, Pakistan, the Philippines, Malaysia and Myanmar.

Read more

Meet Robert Hills, our August volunteer of the month

Voulenteer of the month 2

Professor Robert Hills started volunteering for EHA when he participated in the Clinical Research Training in Hematology (CRTH) program in 2016. This year, Professor Hills started as an Associated Editor for HemaSphere. Meet Professor Hills and learn about what he does and why he's volunteering for EHA.

Read more

Anna Vardi Physician Scientist Research Grant winner 2018

Anna Vardi EHA News 02

Large-scale detection and characterization of T Cells with anti-tumor specificity in chronic lymphocytic leukemia: Can it pave the way for cellular treatments or vaccination strategies?

Read more

Meet our first Physician Scientist Research Grant winner

Award winner Duarte Delfim web 02 02

In 2018, the Physician Scientist Research Grant was awarded for the first time. During the 24th EHA Congress, Delfim Duarte from Porto, Portugal received the award. In a recent interview, Dr Duarte explains how he experienced the application procedure and describes the impact of winning this award.

Read more

Meet Shaun McCann, our July volunteer of the month

Voulenteer of the month Shaun McCann 01

Professor Shaun McCann started volunteering for EHA since the start of the association and is still actively contributing. This year, Professor Shaun McCann was awarded the EHA Education and Mentoring Award. Meet Professor McCann and learn about what he's doing and why he's volunteering for EHA all these years!

Read more

Addressing the bureaucracy challenge

HemAffairs afbeelding 2

EHA has recently brought key stakeholders around the table to discuss bureaucratic obstacles in clinical research. Regulators, patient organizations, the European Commission and industry representatives were invited for a day-long discussion at EHA offices, building on an informal dialogue with the European Medicines Agency (EMA) that had been initiated by a group of prominent clinical researchers.

Read more

FUNDING ALERT: Calls published on ATMPs, T cells and cancer research

HemAffairs afbeelding

In recent weeks, two Calls for proposals were published that offer relevant funding opportunities for hematologists: IMI2 – 18th Call for proposals, a jointly funded partnership between the European Union, and Horizon 2020 – Call for cancer research proposals, call for research proposals in the category ‘Societal Challenge 1 (SC1): Health, demographic change and wellbeing’. . 

Read more

Current status of the Clinical Trials Regulation

AdobeStock 191513461 clinical trials2.jpg

In 2014 the European Parliament approved the Clinical Trials Regulation (CTR) that is supposed to replace the Clinical Trials Directive (CTD) from 2001. Five years later, the regulation has not yet become applicable. What is the aim of the ‘new’ regulation, what issues does it address, and why was its application delayed?

Read more